TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00195663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate placebo
Study: NCT00604695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Intracoronary injection of IV tenecteplase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: Intracoronary injection of IV sterile saline
Study: NCT03512392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative fluid and deresuscitation strategy
Description: Conservative administration of intravenous fluid and active deresuscitation using diuretics or renal replacement therapy for eligible patients
Study: NCT00055731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Study: NCT03512392

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care strategy
Description: Usual care at the discretion of the clinical team
Study: NCT02661867

Intervention type: BEHAVIORAL
Intervention: delivery
Description: delivery either vaginal or by cesarean section

Intervention type: BEHAVIORAL
Intervention: delivery
Description: delivery either vaginal or by cesarean section
Study: NCT02088021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portico Transcatheter Aortic Valve
Description: Placement of the SJM Portico aortic valve with a ALC delivery system
Study: NCT05311787

Intervention type: PROCEDURE
Group type: OTHER
Intervention: esophagectomy with simultaneous reconstruction
Description: Subtotal resection of esophagus and simultaneous reconstruction by gastric pull-up or colon conduit
Study: NCT03363620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic Brackets
Description: arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
Study: NCT00055731

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT04051203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma Injection
Description: 60mL of blood will be drawn from the antecubital vein and processed via centrifugation. Samples will be centrifuged as per manufacturer instructions, yielding 5mL of PRP.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depo-Medrol and lidocaine
Description: Steroid injections will be prepared to include 20mg Depo-Medrol and 2mL 2% lidocaine.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 2mL normal saline.
Study: NCT03897283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib capsules given orally in fasting conditions, dose ranging from 8 mg to 12 mg once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21). Initial dose is 10 mg. If there are no patients with DLT in first treatment cycle , begin to explore dose of 12 mg. If there are 2 or more patients in 3 patients with DLT, 8 mg dose is to explore.
Study: NCT04470063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDO-3055 tablets
Description: Multi-dose for DDO-3055 tablets
Study: NCT04010721

Intervention type: DEVICE
Group type: OTHER
Intervention: Experiment 3
Description: Stimulation total duration from 10 to 600 ms
Study: NCT03549247

Intervention type: BEHAVIORAL
Intervention: quality of life in healthy,gingivitis,periodontitis groups
Description: a questionnaire form evaluating oral hygiene habits and oral hygiene consciousness levels, OHIP-14 scale was applied
Study: NCT04470063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDO-3055 tablets
Description: Multi-dose for DDO-3055 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDO-3055 tablets
Description: Multi-dose for DDO-3055 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multi-dose for Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multi-dose for Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multi-dose for Placebo
Study: NCT04293393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxane
Description: Doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) every 21 days for 4 cycles followed by weekly paclitaxel 80mg/m2 for 12 weeks or 3-weekly docetaxel 100mg/m2 for 4 cycles.
Study: NCT03363620

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic Brackets
Description: arch form development in the orthodontic treatment with 2 different kind of ligation brackets with the same arches protocol in the leveling and alignment phase
Study: NCT04293393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
Study: NCT01162915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stem cells.
Description: Intrathecal infusion of a single dose of ex vivo expanded MSC.
Study: NCT03554447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg tablet plus Pentoxifylline 400Mg Tablet
Description: Selective serotonin reuptake inhibitor plus phosphodiesterase inhibitor with anti-inflammatory properties
Study: NCT04293393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LHRH Analogue
Description: Letrozole 2.5mg orally daily + abemaciclib 150mg orally every 12 hours on a continuous dosing schedule, +/- LHRH analogs in premenopausal women, up to 12 months, in 28-day cycles
Study: NCT03692832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LH
Description: Laparoscopic hysterectomy following AAGL class IV E, vault closed vaginally

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VH
Description: Vaginal hysterectomy following Heaney technique
Study: NCT02130908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lean fish
Description: Participants consumed 150g of lean fish, five times per week for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatty fish
Description: Participants consumed 150g of fatty fish, five times per week for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lean meat
Description: Participants consumed 150g of lean meat, five times per week for 4 weeks
Study: NCT01521650

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Patients will gurgle and swallow a mixture of probiotic bacteria
Study: NCT04661644

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^7 cells/1 mL/vial)
Description: Dose: 1 x 10\^7 cells/1 mL/vial (1,000 clusters of adipose-derived mesenchymal stem cells)
Study: NCT03554447

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram 20 mg tablet + Placebo
Description: Selective serotonin reuptake inhibitor plus placebo
Study: NCT02183233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eschscholtzia Californica

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eschscholtzia Californica Placebo
Study: NCT03747640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self Transcranial Direct Current Stimulation (tDCS)
Description: tDCS with a constant current intensity of 2 milliamps (mA) will be applied for 20 minutes per session daily for 2 weeks (Monday to Friday) via the Soterix 1x1 tDCS mini-CT Stimulator device (Soterix Medical Inc., New York; 6.5 inches long, 3 inches wide, 0.7 inches thick) with headgear and 5x7 cm saline-soaked surface sponge electrodes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness-based meditation
Description: The meditation intervention will be delivered by a recorded device that participants will be given together with the tDCS. All meditation instruction recordings will be done by an experienced mind-body intervention specialist and installed in a user-friendly MP3 player.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Self Transcranial Direct Current Stimulation (tDCS)
Description: For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham meditation
Description: For sham meditation, the participants will be instructed, approximately every 2-3 minutes, to take deep breaths as we sit in meditation. Time spent giving instructions in the sham meditation intervention will be matched to time spent in the mindfulness intervention.
Study: NCT02735954

Intervention type: OTHER
Intervention: Marijuana
Description: This is an observational study looking at the effects of marijuana on health, including lung health and sleep.
Study: NCT04661644

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clusters of adipose-derived mesenchymal stem cells (Dose: 1 x 10^8 cells/1 mL/vial)
Description: Dose: 1 x 10\^8 cells/1 mL/vial (10,000 clusters of adipose-derived mesenchymal stem cells)
Study: NCT02940496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir/Grazoprevir
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Given PO
Study: NCT04374240

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AdNRGM
Description: AdNRGM is an E1-E3 deleted, replication deficient type 5 adenovirus which contains the E. coli NTR gene regulated by the CMV promoter, an internal ribosomal entry site (IRES) and the human GMCSF gene.~CB1954 \[5-(aziridin-1-yl)-2,4-dinitrobenzamide\]
Study: NCT02080299

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning (RIPC)
Description: 3 circles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion, preceding TAVI procedure.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prior to TAVI-procedure, the blood pressure cuff remains uninflated for 30 min.
Study: NCT00538070

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sarcosine
Description: You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sarcosine
Description: You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
Study: NCT00759421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Description: 12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
Study: NCT00691184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine Hydrochloride
Description: 10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Hydrochloride
Description: 1% Terbinafine Hydrochloride Cream, twice a day for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine
Description: Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.
Study: NCT02345213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2020
Description: E2020 tablets will be orally administered once daily after breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets will be orally administered once daily after breakfast
Study: NCT01622465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ergometer cycling
Description: Patients will participate of the exercises program with ergometer cycling and conventional exercises. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional exercises
Description: Patients will participate only of the conventional exercises program. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
Study: NCT01290744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: Clofazimine 100mg daily for 12 months after completion of MDT.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily for 12 months
Study: NCT00898833

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT04994301

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung T1 MRI
Description: Evaluation of lung T1 MRI to Assess Lung Disease
Study: NCT01192308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen 40mg QD
Description: Tamoxifen 40mg QD during 4 weeks
Study: NCT04325620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1601
Description: HIP1601

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HGP1805
Description: Placebo of HIP1601
Study: NCT01424033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 600mg by mouth, three times daily for 12 months
Study: NCT03549247

Intervention type: BEHAVIORAL
Intervention: quality of life in healthy,gingivitis,periodontitis groups
Description: a questionnaire form evaluating oral hygiene habits and oral hygiene consciousness levels, OHIP-14 scale was applied

Intervention type: BEHAVIORAL
Intervention: quality of life in healthy,gingivitis,periodontitis groups
Description: a questionnaire form evaluating oral hygiene habits and oral hygiene consciousness levels, OHIP-14 scale was applied
Study: NCT04448210

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DigiKnowIt News: Teen
Description: Teens will interact with a multimedia educational website that will teach them about pediatric clinical trials including topics such as participant rights and safety, benefits and costs to participating in a study, and different types of procedures used in trials.
Study: NCT01991002

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 14/21 diet
Description: Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.~The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group.
Study: NCT02485106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: 400mg three times per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid or pentoxifylline
Description: Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid or pentoxifylline
Description: Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days
Study: NCT00165425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echo/Stress Echo
Description: Participants will under resting echocardiogram and stress echocardiogram (echo and stress echo) and the results will be interpreted by a cardiologist
Study: NCT01314209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion
Study: NCT04109664

Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastrectomy
Description: The greater omentum is carefully dissected from the stomach at a distance of 2cm for the patients with AR, and 6cm for patients with AP. The omental dissection was performed using 5mm-abdominal ligature (Ligasure®, Metronic-Covidien, Minneapolis, USA), from the antrum towards the angle of His. Transection from the omentum is continued until the left crus has been identified. All sleeves are transected using 36 French orogastric tubes. Green cartridges (4.8 mm staple height) are used for the first firing and blue cartridges (3.5 mm) for the rest. Neither oversewing sutures to the staple line nor staple line reinforcement products are used. Homeostatic metallic clips are used for bleeding at the staple line. If bleeding persists and cannot be controlled, an interrupted suture is performed at the point of bleeding. A leak test with methylene blue is performed to the gastric remnant to assess the integrity of the suture line.

Intervention type: PROCEDURE
Intervention: laparoscopic sleeve gastrectomy
Description: The greater omentum is carefully dissected from the stomach at a distance of 2cm for the patients with AR, and 6cm for patients with AP. The omental dissection was performed using 5mm-abdominal ligature (Ligasure®, Metronic-Covidien, Minneapolis, USA), from the antrum towards the angle of His. Transection from the omentum is continued until the left crus has been identified. All sleeves are transected using 36 French orogastric tubes. Green cartridges (4.8 mm staple height) are used for the first firing and blue cartridges (3.5 mm) for the rest. Neither oversewing sutures to the staple line nor staple line reinforcement products are used. Homeostatic metallic clips are used for bleeding at the staple line. If bleeding persists and cannot be controlled, an interrupted suture is performed at the point of bleeding. A leak test with methylene blue is performed to the gastric remnant to assess the integrity of the suture line.
Study: NCT01747083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))
Study: NCT01169506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sublingual silicon capillary
Description: Stable patients with COPD and healthy individuals were asked to open their mouth and a small butterfly silicon capillary was placed sublingually. After 15 minutes, while the mouth was closed completely and nose breathing was performed, the capillary system was connected to a capnometer and sublingual tonometric PCO2 was measured. At the same time, PETCO2 was also measured and arterial blood was drawn for pH, PO2 and PCO2 analysis
Study: NCT01553006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefditoren pivoxil
Description: comparison of different dosages of cefditoren pivoxil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefditoren pivoxil
Description: comparison of different dosages of cefditoren pivoxil
Study: NCT00578942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath Purged Non-myeloablative ASCT
Description: Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Subject Evaluation will occur 2-3 times per week by physical exam for toxicity through day 45.
Study: NCT03075670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N9-GP
Description: A single dose of 50 IU/kg for intravenous (i.v.) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALPROLIX®
Description: A single dose of 50 IU/kg for intravenous (i.v.) injection
Study: NCT03044132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DermACELL AWM
Description: Decellularized regenerative human tissue matrix allograft (dermis) processed using proprietary Matracell® technology
Study: NCT01215227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preladenant
Description: Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)
Study: NCT02439216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edasalonexent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edasalonexent